2024
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo P, Zarif T, McClure H, Davidsohn M, Eid M, Spinelli G, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre R, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E, Group S. Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study. Clinical Genitourinary Cancer 2024, 22: 102230. PMID: 39461026, DOI: 10.1016/j.clgc.2024.102230.Peer-Reviewed Original ResearchMeSH KeywordsAbiraterone AcetateAgedAged, 80 and overAndrogen Receptor AntagonistsBenzamidesDocetaxelHumansMaleNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantRetrospective StudiesTreatment OutcomeConceptsMetastatic castration-resistant prostate cancerAndrogen receptor signaling inhibitorsCastration-resistant prostate cancerAbiraterone acetateOverall survivalProstate cancerElderly patientsSignaling inhibitorsCohort of consecutive patientsSecond-line therapyStandard first-lineReal-world studySecond-lineConsecutive patientsTreatment toxicityFirst-lineD. CONCLUSIONSPatient comorbiditiesIdentified patientsRetrospective designToxicity outcomesD groupInternational cohortPatientsNo differenceCirculating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Hussain M, Quinn D, Dorff T, Lerner S, Thompson I, Agarwal N. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2437871. PMID: 39374015, PMCID: PMC11581504, DOI: 10.1001/jamanetworkopen.2024.37871.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorHumansMaleMiddle AgedNeoplasm MetastasisNeoplastic Cells, CirculatingPrognosisProspective StudiesProstate-Specific AntigenProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantConceptsMetastatic hormone-sensitive prostate cancerMetastatic castration-resistant prostate cancerCirculating tumor cell countCirculating tumor cellsHormone-sensitive prostate cancerTumor cell countOverall survivalProstate cancerPrognostic valueCTC countsPrognostic factorsProgression to metastatic castration-resistant prostate cancerDiagnosed mHSPCPeripheral blood circulating tumor cellsClinical trialsBlood circulating tumor cellsCastration-resistant prostate cancerPrognostic studyCell countBaseline CTC countProgression-free survivalLines of therapyEnhanced overall survivalProstate-specific antigenIncreased prognostic valueThe Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART)
Chakrani Z, Patel M, Mellgard G, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Ganta T, Patel V. The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). Clinical Genitourinary Cancer 2024, 22: 102227. PMID: 39437664, DOI: 10.1016/j.clgc.2024.102227.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen Receptor AntagonistsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMolecular Targeted TherapyProgression-Free SurvivalProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRetrospective StudiesSurvival RateTreatment OutcomeConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesPSA progression free survivalOverall survivalConcurrent statinSurvival outcomesStatin useSingle-institution retrospective analysis of patientsHazard ratioSingle-institution retrospective analysisCastration-resistant prostate cancerRetrospective analysis of patientsConcurrent statin useAssociation of statin useProgression free survivalReceptor-targeted therapyCox proportional hazards regression modelsOutcomes of patientsAnalysis of patientsMultivariate survival analysisProportional hazards regression modelsTumor cell viabilityMultivariate logistic regressionHazards regression modelsEstimate hazard ratiosOutcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo P, Zanardi E, Rossetti S, Davidsohn M, Eid M, Zarif T, McClure H, Spinelli G, Damassi A, Murianni V, Vauchier C, Oliveira T, Malgeri A, Modesti M, Mestre R, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E, Group S. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study. Clinical Genitourinary Cancer 2024, 22: 102185. PMID: 39217072, DOI: 10.1016/j.clgc.2024.102185.Peer-Reviewed Original ResearchMeSH KeywordsAbiraterone AcetateAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzamidesDocetaxelHumansMaleNitrilesPhenylthiohydantoinPrednisoneProstatic Neoplasms, Castration-ResistantRegistriesRetrospective StudiesTreatment OutcomeConceptsMetastatic castration-sensitive prostate cancerMetastatic castration-resistant prostate cancerAbiraterone acetate plus prednisoneAndrogen deprivation therapyCancer-specific survivalCastration-sensitive prostate cancerFirst-line therapyProstate cancerAdverse eventsFailure of androgen deprivation therapyMedian cancer-specific survivalCastration-resistant prostate cancerAcetate plus prednisoneInternational multicenter registryMedian follow-upKaplan-Meier methodFirst-line treatmentUpfront docetaxelDeprivation therapyAbiraterone acetatePrimary endpointSurvival outcomesMulticenter registryADT+DFollow-upPerformance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy
Mellgard G, Saffran N, Chakrani Z, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 459-464. PMID: 39087466, DOI: 10.1097/coc.0000000000001115.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen Receptor AntagonistsHumansMaleMiddle AgedMolecular Targeted TherapyProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRetrospective StudiesSurvival RateTerminal CareConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerPerformance statusProstate cancerOverall survivalAndrogen receptor-targeted therapiesCompare overall survivalReceptor-targeted therapyReduced performance statusSingle-institution studyCompare baseline characteristicsAssessment of PSFisher's exact testWilcoxon signed-rank testTaxane chemotherapyShorter OSCompare OSSigned-rank testTargeted therapyTreatment courseAndrogen receptorBaseline characteristicsExact testCox regressionART treatmentRisk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy
Chakrani Z, Mellgard G, Saffran N, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 271-278. PMID: 38344754, DOI: 10.1097/coc.0000000000001087.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen Receptor AntagonistsHumansMaleMiddle AgedMolecular Targeted TherapyProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRetrospective StudiesRisk FactorsWithholding TreatmentConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesReceptor-targeted therapyTreatment discontinuationSingle-institution retrospective review of patientsDiscontinued treatment due to toxicityTreatment discontinuation due to toxicityDiscontinued due to toxicityMultivariate analysisTreatment due to toxicityCastration-resistant prostate cancerSingle-institution retrospective reviewRetrospective review of patientsRisk of treatment discontinuationRisk factorsPatient-reported side effectsPatients discontinued treatmentTreatment-related toxicityEarly treatment discontinuationReview of patientsImprove survival outcomesDuration of treatmentLikelihood of treatment discontinuationProgression of diseaseTreatment toxicityOvercoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate
Ou Y, Chu G, Lyu J, Yin L, Lim A, Zhai N, Cui X, Lewis M, Edderkaoui M, Pandol S, Wang R, Zhang Y. Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate. Molecular Pharmaceutics 2024, 21: 873-882. PMID: 38229228, PMCID: PMC11025579, DOI: 10.1021/acs.molpharmaceut.3c00993.Peer-Reviewed Original ResearchMeSH KeywordsCarbocyaninesCell Line, TumorHumansMaleProstateProstatic Neoplasms, Castration-ResistantSimvastatinConceptsProstate cancerTherapeutic resistanceTarget PC cellsAndrogen receptor statusTraditional systemic treatmentsSuppressed xenograft tumor formationProstate cancer therapyCastration-resistant formTumor cell targetsPC cellsSignificant side effectsCancer-related deathsCell deathHeptamethine carbocyanine dyeXenograft tumor formationPC cell linesXenograft tumor modelReceptor statusHormone therapySystemic treatmentSafety profileTumor cellsChemotherapeutic drugsTumor modelCancer therapyMechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC
Panja S, Truica M, Yu C, Saggurthi V, Craige M, Whitehead K, Tuiche M, Al-Saadi A, Vyas R, Ganesan S, Gohel S, Coffman F, Parrott J, Quan S, Jha S, Kim I, Schaeffer E, Kothari V, Abdulkadir S, Mitrofanova A. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nature Communications 2024, 15: 352. PMID: 38191557, PMCID: PMC10774320, DOI: 10.1038/s41467-024-44686-5.Peer-Reviewed Original ResearchAndrogen Receptor AntagonistsBenzamidesHumansMaleNM23 Nucleoside Diphosphate KinasesProstatic Neoplasms, Castration-ResistantSignal Transduction
2023
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance
Rodriguez Tirado C, Wang C, Li X, Deng S, Gonzalez J, Johnson N, Xu Y, Metang L, Sundar Rajan M, Yang Y, Yin Y, Hofstad M, Raj G, Zhang S, Lemoff A, He W, Fan J, Wang Y, Wang T, Mu P. UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. Oncogene 2023, 43: 265-280. PMID: 38030789, PMCID: PMC10798893, DOI: 10.1038/s41388-023-02890-5.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen AntagonistsAndrogensCell Line, TumorHumansMaleProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantProteolysisReceptors, AndrogenUbiquitin-Conjugating EnzymesConceptsAberrant androgen receptorProstate cancerAR ubiquitinationAR degradationAntiandrogen therapyResistance to antiandrogen therapyE2 ubiquitin-conjugating enzymeEnhanced AR signalingAndrogen receptor degradersAR protein levelsProstate cancer patientsUbiquitin-conjugating enzymeResistant tumorsPCa tumorsAR signalingAndrogen receptorAntiandrogen treatmentAntiandrogen resistanceAR proteinReceptor degradationProtein levelsOncogenic proteinsTumorTherapyProtein degradation processMaster transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer.
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song W, Fujiwara N, Li P, Mendizabal I, Petrylak D, Kelly W, Reddy E, Wang L, Schiewer M, Lujambio A, Karnes J, Knudsen K, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discovery 2023, 13: 2584-2609. PMID: 37676710, PMCID: PMC10714140, DOI: 10.1158/2159-8290.cd-23-0306.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen AntagonistsCastrationHumansImmune EvasionMaleProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTranscription FactorsConceptsLethal prostate cancerProstate cancerCastration resistanceImmune evasionPharmacologic targetingAnti-PD-1 therapyMajor histocompatibility complex IDeprivation therapyMicrophthalmia transcription factorAndrogen receptorPreclinical modelsTherapeutic strategiesCancerTherapyDruggable mechanismMaster transcription factorTranscription factorsKey mRNAsSpecific mRNAsMRNAFactor 3bEvasionSelected ArticlesTargetingTumorsThe Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer.
Li X, Mu P. The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer. Cancer Research 2023, 83: 2990-2992. PMID: 37504898, DOI: 10.1158/0008-5472.can-23-2260.Commentaries, Editorials and LettersMeSH KeywordsAndrogen AntagonistsAnimalsDisease ProgressionDrug Resistance, NeoplasmHumansMaleMiceNeoplasm Recurrence, LocalProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTumor MicroenvironmentConceptsCastration-resistant prostate cancerAndrogen deprivation therapyProstate cancerAndrogen receptorCastration-resistant prostate cancer developmentDevelopment of castration-resistant prostate cancerGenetically engineered mouse modelsMyofibroblastic cancer-associated fibroblastsOvercome treatment resistanceCancer-associated fibroblastsIncreased tumor heterogeneityDeprivation therapyCRPC developmentProstate tumorsTumor microenvironmentLineage plasticityTreatment resistanceStromal compartmentStandard treatmentTumor heterogeneityCancer recurrenceDrug resistanceDisease progressionMouse modelSingle-cell RNA sequencingThe Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Armstrong A, Iguchi T, Azad A, Villers A, Alekseev B, Petrylak D, Szmulewitz R, Alcaraz A, Shore N, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas G, Gourgiotti G, El-Chaar N, Stenzl A. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. European Urology 2023, 84: 229-241. PMID: 37179240, DOI: 10.1016/j.eururo.2023.04.002.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen AntagonistsAndrogensDisease-Free SurvivalHumansMaleProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantTreatment OutcomeConceptsHormone-sensitive prostate cancerAndrogen deprivation therapyRadiographic progression-free survivalMetastatic hormone-sensitive prostate cancerOligometastatic hormone-sensitive prostate cancerOverall survivalProstate cancerDeprivation therapyHazard ratioAndrogen receptor inhibitionEarly treatment intensificationEfficacy of enzalutamideRisk of undertreatmentSystemic treatment strategiesSecondary efficacy endpointsPhase 3 studyProgression-free survivalNumber of metastasesConfidence intervalsProportional hazards modelPost Hoc AnalysisEfficacy endpointOligometastatic diseaseSecondary endpointsTreatment intensificationCombination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Antonarakis E, Subudhi S, Pieczonka C, Karsh L, Quinn D, Hafron J, Wilfehrt H, Harmon M, Sheikh N, Shore N, Petrylak D. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research 2023, 29: 2426-2434. PMID: 37058234, PMCID: PMC10320463, DOI: 10.1158/1078-0432.ccr-22-3832.Peer-Reviewed Original ResearchMeSH KeywordsAbiraterone AcetateHumansMaleNitrilesProstatic Neoplasms, Castration-ResistantTissue ExtractsTreatment OutcomeConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted agentsMedian overall survivalCastration-resistant prostate cancerOverall survivalNational Death IndexConcurrent administrationProstate cancerAntigen-presenting cell activationCurrent prescribing informationNew safety signalsKaplan-Meier methodologyLong-term outcomesConfidence intervalsReceptor-targeted agentsProstatic acid phosphataseAbiraterone acetateFirst infusionDeath IndexPrescribing informationHumoral responseSubsequent infusionSequential administrationSafety signalsImmune responseExternal Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Halabi S, Yang Q, Roy A, Luo B, Araujo J, Logothetis C, Sternberg C, Armstrong A, Carducci M, N. K, de Bono J, Petrylak D, Fizazi K, Higano C, Morris M, Rathkopf D, Saad F, Ryan C, Small E, Kelly W. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal Of Clinical Oncology 2023, 41: 2736-2746. PMID: 37040594, PMCID: PMC10414709, DOI: 10.1200/jco.22.02661.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsDocetaxelHumansMalePrognosisProportional Hazards ModelsProstatic Neoplasms, Castration-ResistantTreatment OutcomeConceptsOverall survivalPrognostic modelPrognostic groupsRisk groupsProstate cancerChemotherapy-Naïve Metastatic CastrationLow-risk prognostic groupsCastration-resistant prostate cancerPrognostic risk groupingsIntermediate-risk groupMedian overall survivalPhase III trialsGroup of patientsPrognostic risk groupsResistant prostate cancerRandomized clinical trialsTime-dependent areaDifferent treatment classesIII trialsInhibitor trialsRisk groupingClinical trialsTreatment subgroupsSpecific subgroupsTrial statusFirst-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
Autio K, Higano C, Nordquist L, Appleman L, Zhang T, Zhu X, Babiker H, Vogelzang N, Prasad S, Schweizer M, Madan R, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang I, Zheng J, Tang S, Hollingsworth R, Kern K, Petrylak D. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). Journal For ImmunoTherapy Of Cancer 2023, 11: e005702. PMID: 36948505, PMCID: PMC10040068, DOI: 10.1136/jitc-2022-005702.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen AntagonistsDocetaxelHormonesHumansImmunotherapyMaleProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantVaccinesConceptsMetastatic castration-resistant prostate cancerAndrogen deprivation therapyRadiographic progression-free survivalCastration-resistant prostate cancerPhase 1 studyBiochemical recurrenceProstate cancerImmunotherapy regimenMedian durationDose escalationMedian radiographic progression-free survivalAntigen-specific T cell responsesImmune-related adverse eventsRecommended phase 2 doseSpecific T cell responsesPhase 2 doseImmune checkpoint inhibitorsModest antitumor activityObjective response rateProgression-free survivalAntigen-specific immunityT cell responsesInfluenza-like illnessSignificant side effectsDeprivation therapyManagement of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal Of Cancer 2023, 185: 178-215. PMID: 37003085, DOI: 10.1016/j.ejca.2023.02.018.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate Cancer Consensus ConferenceAdvanced prostate cancerHormone-sensitive prostate cancerOligometastatic prostate cancerProstate cancerNon-metastaticConsensus conferenceConsensus questionsTreatment optionsMetastatic hormone-sensitive prostate cancerAdvanced prostate cancer managementInternational prostate cancer expertsLocally advanced prostate cancerAdvanced prostate cancer treatmentEffects of hormone therapySide effects of hormone therapyMetastatic hormone-sensitiveOligoprogressive prostate cancerProstate cancer expertsProstate cancer managementLevel 1 evidenceNovel treatment optionsOptimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. The Oncologist 2023, 28: 246-251. PMID: 36651837, PMCID: PMC10020806, DOI: 10.1093/oncolo/oyac245.Peer-Reviewed Original ResearchMeSH KeywordsBone and BonesBone NeoplasmsHumansMaleProstatic Neoplasms, Castration-ResistantRadiumRetrospective StudiesConceptsBaseline BSIBone scan indexMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerOverall survivalSkeletal metastasesRa-223 therapyRa-223 treatmentRadium-223 treatmentTreatment-associated reductionChemotherapy-naïve patientsMedian overall survivalAbsolute neutrophil countRadium-223 dichlorideHigh serum PSANovel treatment modalitiesAlkaline phosphatase levelsChemotherapy-naïveTreatment tolerabilityNeutrophil countSerum PSABone scanLaboratory parametersPatient selection
2022
Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
Liaw B, Tsao C, Seng S, Jun T, Gong Y, Galsky M, Oh W. Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. The Oncologist 2022, 28: 366-e224. PMID: 36519763, PMCID: PMC10078918, DOI: 10.1093/oncolo/oyac224.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsDocetaxelHumansMaleMiddle AgedProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantTissue Inhibitor of Metalloproteinase-1Treatment OutcomeConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerMetastatic castration-resistant prostate cancer patientsImproved time to disease progressionDNA damage repair mutationsTime to disease progressionBlood RNA signatureOral platinum analoguePlatinum-based chemotherapyPhase II studySerum tissue inhibitorAssociated with platinum responseTissue-based biomarkersPeripheral blood samplesMCRPC patientsMedian PSABlood biomarker measurementsII studyPlatinum responseBlood-based biomarkersSPARC trialPlatinum analoguesTissue inhibitorDay 1Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, N. K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O’Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology 2022, 83: 267-293. PMID: 36494221, PMCID: PMC7614721, DOI: 10.1016/j.eururo.2022.11.002.Peer-Reviewed Original ResearchMeSH KeywordsHumansMaleNeoplasm Recurrence, LocalProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantConceptsAdvanced Prostate Cancer Consensus ConferenceAdvanced prostate cancerProstate Cancer Consensus ConferenceLocally advanced prostate cancerCastration-resistant prostate cancerProstate cancerBiochemical relapseSide effectsHormone therapyTreatment optionsMetastatic hormone-sensitive prostate cancerNonmetastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerClinical managementInternational prostate cancer expertsLack high-level evidenceHormone-sensitive prostate cancerProstate cancer treatment decision-makingTreatment decisionsHigh riskConsensus conferenceOligoprogressive prostate cancerProstate cancer expertsLocally advanced diseaseManagement of patientsRandomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. Journal Of Clinical Oncology 2022, 41: 871-880. PMID: 36256912, PMCID: PMC9901975, DOI: 10.1200/jco.21.02947.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleNational Cancer Institute (U.S.)PhthalazinesProstatic Neoplasms, Castration-ResistantUnited StatesVascular Endothelial Growth Factor AConceptsMetastatic castration-resistant prostate cancerRadiographic progression-free survivalMedian radiographic progression-free survivalCastration-resistant prostate cancerArm AProstate cancerAdverse eventsGrade 3Progressive metastatic castration-resistant prostate cancerEndothelial growth factor receptor inhibitorEnd pointHomologous recombination repair genesGrowth factor receptor inhibitorsPrimary end pointSecondary end pointsProgression-free survivalRecombination repair genesPoly (ADP-ribose) polymerase inhibitionTreat setTreat patientsClinical outcomesRandomized trialsPreclinical modelsReceptor inhibitorsCediranib
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply